Axol Bioscience Ltd.’s Post

Looking to build in vitro cardiotoxicity and cardiac models to assess drug safety or for cardiac research? Let's have a conversation! Ventricular cardiomyocytes represent those found in the ventricles of the human heart. They are frequently used to fuel in vitro cardiotoxicity models to assess drug safety and for cardiac research, and can be used in co-culture with other cells, including atrial cardiomyocytes. Historically, a range of cardiotoxicity models have been used, including ex vivo and in vivo (animal) models, primary cell models (using cells taken directly from humans or animals), and in vitro immortalized cells expressing certain ion channels critical for cardiac function. In recent years, the industry has turned to more human-relevant model systems powered by human iPSC-derived cells to bridge the translational gap from bench to bedside that has hindered drug discovery and toxicology. axoCells™ human iPSC-derived ventricular cardiomyocytes can power advanced in vitro platforms for models investigating. Key highlights include: • Spontaneously beat 3 days post-thaw and are assay-ready in just 7 days • Validated against all 28 CiPA compounds • Demonstrate functional responses in a range of assay formats including patch clamp, electrophysiology and voltage-sensitive dyes • Manufactured in our ISO 9001-accredited production facility with excellent ISSCR Standards compliance Click here to read about the CiPA validation of our axoCells ventricular cardiomyocytes. In this application note we show that axoCells ventricular cardiomyocytes have applications for in vitro cardiac safety testing and detection of pro-arrhythmic risk of new compounds. https://hubs.la/Q02Mb3tJ0 With a full complement of offerings and decades of in-house expertise, get in contact and see why we've become the first choice for cardiac researchers looking to use iPSC technology. Email us at operations@axolbio.com and let us know what we can do to help! #iPSCs #cardiotoxicity #StemCells #MPS #VentriclularCardiomyocytes

Looking to build in vitro cardiotoxicity and cardiac disease models? Read about our work and download our new 2024 Cardiac Guide! Last week, we attended the Society of Toxicology 63rd Annual Meeting and ToxExpo, discussing our work using human iPSCs for cardiotoxicity and neurotoxicity screening. We received an incredible response to our cardiotoxicity offerings, including: • A new axoCells™ Atrial Kit product, offering an all-in-one bundle for in vitro atrial fibrillation modeling • Two exciting concepts that we're working on, with a view to enhancing the purity and maturity of iPSC-derived cardiotoxicity models • Our range of capabilities to support cardiac safety researchers including custom lab services, iPSCs and collaborative model building We've rounded up our cardiac and cardiotoxicity offerings into our 2024 Cardiac Guide, which you can download by clicking the link in the article below. https://hubs.ly/Q02pMZh80 If you'd like to discuss a project, get in contact at operations@axolbio.com #iPSCs #cardiotoxicity #CiPA #AtrialFibrillation #SOT2024

Looking to build in vitro cardiotoxicity and cardiac disease models? Read about our work and download our new 2024 Cardiac Guide! Last week, we attended the Society of Toxicology 63rd Annual Meeting and ToxExpo, discussing our work using human iPSCs for cardiotoxicity and neurotoxicity screening. We received an incredible response to our cardiotoxicity offerings, including: • A new axoCells™ Atrial Kit product, offering an all-in-one bundle for in vitro atrial fibrillation modeling • Two exciting concepts that we're working on, with a view to enhancing the purity and maturity of iPSC-derived cardiotoxicity models • Our range of capabilities to support cardiac safety researchers including custom lab services, iPSCs and collaborative model building We've rounded up our cardiac and cardiotoxicity offerings into our 2024 Cardiac Guide, which you can download by clicking the link in the article below. https://hubs.la/Q02pMYMs0 If you'd like to discuss a project, get in contact at operations@axolbio.com #iPSCs #cardiotoxicity #CiPA #AtrialFibrillation #SOT2024

𝗥𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗰𝗮𝗿𝗱𝗶𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻: 𝗔𝘁𝗹𝗮𝗭 𝗵𝗲𝗹𝗽𝘀 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝘆 𝗱𝗿𝘂𝗴 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 🫀🔬 Long-term exposure to cancer-related therapeutics can impair cardiac function in patients. To study the effects of different drugs on cardiomyoblasts, we monitored the H9C2 cell line using the AtlaZ platform. We tested reference compounds with different mechanisms of action (MoAs) on cardiomyocytes, affecting cardiac energetics, contractility, electrophysiology or myofilament organization. AtlaZ gives you a unique richness of information, label-free, in real-time, with high-throughput. Access kinetic and phenotypic information to help you see how cells die – analyzing six 96-well plates simultaneously or independently. Curious? Learn more: https://ow.ly/eZtO50QOMkl 𝗔𝗿𝗲 𝗬𝗼𝘂 𝗔𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗦𝗢𝗧 𝟮𝟬𝟮𝟰? 📰Catch us today from 9:15 – 11:15 AM (MST) at 𝗽𝗼𝘀𝘁𝗲𝗿 #𝗣𝟳𝟰𝟲. Let’s dive deeper into the topic: “AtlaZ as a High-Throughput System for Advanced Functional Cell Analysis in Toxicology and Immuno-oncology.” We look forward to connecting with you at SOT! #TeamNanion #CellAnalytics #CardioExcyte96 #FLEXcyte96 #AtlaZ #Cardiotoxicity #SOT #SOT2024

Targeting Meis1 and Hoxb13 transcriptional activity could be a viable therapeutic strategy for heart regeneration. In a recent study, FDA-approved drugs Paromomycin and Neomycin showed promising results in inhibiting Meis1 and Hoxb13 transcriptional activity, which induced proliferation of neonatal rat ventricular myocytes in vitro. In adult mice and pigs after cardiac ischemia/reperfusion injury, administration of Paro-Neo combination led to cardiomyocyte proliferation, improved left ventricular systolic function, and decreased scar formation. These findings identify FDA-approved drugs with therapeutic potential for inducing heart regeneration in mammals. #HeartRegeneration #FDAApprovedDrugs #MedicalResearch https://lnkd.in/drAXn5gq

Pleased to share the publication of this exploratory study in Clinical and Translational Science, conducted at one of our CTC Clinical Trial Consultants AB units in collaboration with Vicore Pharma AB. Exploratory studies are indeed useful in early drug development, and can provide insights into the mechanism of action and pharmacodynamics at an early stage. This is helpful when making informed developmental decisions. Administering sub-therapeutic doses locally in the body allow for obtaining MOA and PD data while minimising risk of systemic effects to volunteers. If you happen to evaluate a symmetrical organ, you also have the advantage of a contemporaneous control. In this exploratory early phase study, we evaluated dose–response related vasodilative effects of C21, a potent and selective angiotensin II type 2 receptor (AT2R) agonist. This was done using venous occlusion plethysmography, combined with microdoses infused intra-arterially. Thanks to all co-authors, team members and healthy volunteers!

🔔 New article alert! Read our latest open-access article "Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist". It's published in Clinical and Translational Science and put together by our colleague Erik and co-authors from CTC and Vicore Pharma AB! Get the link in the post below! 👇

🚨 Hot off the press 🚨 „Immunomodulatory imide drugs inhibit human detrusor smooth muscle contraction and growth of human detrusor smooth muscle cells, and exhibit vaso-regulatory functions“ Happy to share our groundbreaking data on effects of immunomodulatory drugs (#IMiDs) in the lower urinary tract and vasculatute, which may alter our understanding of basic #physiology and #cell #proliferation in smooth muscle-rich organs. These data have already received significant recognition with Best Poster Award at last year‘s #AUA23 in #Chicago and the prestigious Winfried Vahlensieck Award at #DGU2023. Data are from our #research group focusing on basic and clinical research in #urological diseases, particularly benign prostatic hyperplasia, voiding dysfunction, overactive bladder, minimally invasive surgery, and urological #oncology. Special thanks to Ludwig-Maximilians-Universität München LMU Klinikum München, Department of #Urology and Helmholtz Munich for providing the necessary research facilities, and for #funding through the esteemed Ferdinand Eisenberger grant by Deutsche Gesellschaft für Urologie, sponsored by The Janssen Pharmaceutical Companies of Johnson & Johnson Johnson & Johnson and through Munich Medical and Clinician Scientist Program (MCSP) by Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation. With novel insights gained from basic scientific research, we will provide bench to bedside #translational solutions for the treatment and #care of #LUTS #BPH and #OAB by introducing novel #pharmaceutical options in the #future! Bristol Myers Squibb Elsevier #healthcare #research #project #growth #leadership #luts #bph #germany #munich #benchtobedside #revlimid #biomedicine #pharma #pharmacotherapy #pharmacology

AlzeCure Pharma is presenting preclinical data with its lead drug candidate NeuroRestore ACD856 at the Alzheimer's congress AD/PD 2024, which will be held in Lisbon on March 5-9. The abstract and poster is titled ”ACD856 is a biased positive allosteric modulator of Trk-receptors - Enhances neurite outgrowthbut do not affect pain signaling” is by Pontus Forsell, Head of Discovery and Research at AlzeCure with co-authors Veronica Lidell, Azita Rasti, Gunnar Nordvall and Johan Sandin. The presentation includes study results showing that ACD856, the lead drug candidate in the NeuroRestore platform being developed with a focus on Alzheimer's disease, selectively appears to potentiate some signaling pathways, but not others. New preclinical data show that the substance stimulates the growth of nerve cell projections, which can promote nerve cell communication, but does not affect other functions, such as pain signaling. Previous studies have also been able to show that ACD856 improves memory, synaptic plasticity and has neuroprotective properties. “The selective effects of ACD856 are a strength for the continued clinical studies and show that substances from the project can have potent effects while maintaining a good safety profile,” said Pontus Forsell. “These positive data are very important for AlzeCure as we can now continue the development of this potential blockbuster in Alzheimer's disease where there is still a great medical need," said Martin Jönsson, CEO of AlzeCure Pharma. The abstract and the poster will be available on AlzeCure’s website after the presentation at AD/PD. More at: https://lnkd.in/dasgr2VH #alzecure #neurorestore #acd856 #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #trkpam #bdnf #bdnfmodulator